Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

Johnson & Johnson (NYSE: JNJ) reported new Phase 3 results for oral peptide ICOTYDE in plaque psoriasis at the 2026 EADV Congress. The oral IL-23 inhibitor showed sustained skin clearance and improvement across multiple high-impact psoriasis sites, including in adolescent patients. Johnson & Johnson said ICOTYDE also remains in clinical studies for other major inflammatory diseases beyond plaque psoriasis. The fresh ICOTYDE Phase 3 data matters, but investors should weigh it alongside...